🏛️ Verified NIH Record • Updated 2025-12-02
Preventing Asthma in High Risk Kids (NCT02570984)
Controlling and Preventing Asthma Progression and Severity in Kids
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Boston Children's Hospital
🩺 Plain-English Summary (8th-Grade Level)
This trial is a randomized, double-blind, placebo controlled trial designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2 year observation period off study drug.
Who can join: Review the eligibility criteria below.
Location: Phoenix Children's Hospital — Phoenix, Arizona
Age range: 24 Months to 47 Months
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Phoenix Children's Hospital — Phoenix, Arizona
- Rady Children's Hospital - San Diego — San Diego, California
- Childrens Hospital Colorado — Aurora, Colorado
- Connecticut Children's Hospital — Hartford, Connecticut
- Children's National Medical Center — Washington D.C., District of Columbia
- Emory University — Atlanta, Georgia
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
- Indiana University/Riley Children's Hospital — Indianapolis, Indiana
- Boston Children's Hospital — Boston, Massachusetts
- Washington University — St Louis, Missouri
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Texas Children's Hospital/Baylor College of Medicine — Houston, Texas
- University of Wisconsin — Madison, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Asthma
- Investigating Dupilumab's Effect in Asthma by Genotype — Boston, Massachusetts
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Bakersfield, California
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Saraland, Alabama
- Reduce IDentified UNcontrolled Asthma — San Diego, California
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma — Little Rock, Arkansas
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study — La Jolla, California
Explore by condition: All Asthma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.